EVLO - Evelo Biosciences, Inc.
Chart Events
MACD
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.1055 |
| Open | 0.1095 |
| Bid | 0.1060 x 2900 |
| Ask | 0.1075 x 900 |
| Day's Range | 0.1060 - 0.1170 |
| 52 Week Range | 0.0240 - 3.2900 |
| Volume | |
| Avg. Volume | 3,963,750 |
| Market Cap | 11.883M |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0500 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.40 |
Fair Value
Related Research
ZacksWhat Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock
Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PR NewswireFlagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's MIMiC™ platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications.
Simply Wall St.Evelo Biosciences Insiders Added US$575k Of Stock To Their Holdings \
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
BenzingaEvelo Biosciences' Atopic Dermatitis Study Cohort Misses Primary Goal Again, Shuts Study, Lays Off More Staff
Evelo Biosciences Inc (NASDAQ: EVLO) said its fourth cohort of the EDP1815 Phase 2 trial in atopic dermatitis, consistent with the first three cohorts, failed to meet the primary endpoint of the proportion of patients who achieve an EASI-50 response at week 16. EASI-50 responses or greater were achieved at week 16 in 37.9% of patients dosed with EDP1815 versus 44.7% on placebo in the fourth cohort. Following the results, the company decided to cease further development of EDP1815 in atopic derma
American City Business JournalsFlagship-backed startup makes layoffs for second time in three months
Just under three months after it laid off nearly half its staff, a Flagship Pioneering spinout is making cuts again.
GlobeNewswireEvelo Biosciences Provides Clinical Updates
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint –– Company will focus on development of extracellular vesicles (EVs) –– First EV candidate, EDP2939, in Phase 2 moderate psoriasis study fully enrolled; data anticipated in early Q4 2023 –– Management to host conference call today at 8:30 a.m. ET – CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing
Insider MonkeyEvelo Biosciences, Inc. (NASDAQ:EVLO) Q4 2022 Earnings Call Transcript
Evelo Biosciences, Inc. (NASDAQ:EVLO) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good morning and welcome to the Evelo Biosciences Conference Call to discuss its Fourth Quarter and Full Year 2022 Financial Results and Business Update. Please be advised this call is being recorded at the company’s request. At this time, I’d like to […]
- Thomson Reuters StreetEvents
Q4 2022 Evelo Biosciences Inc Earnings Call
Q4 2022 Evelo Biosciences Inc Earnings Call
- GlobeNewswire
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the fourth quarter and full year 2022. “We continued to progress on our SINTAX platform and our clinical pipeline in 2022. We look forward to important cl
- GlobeNewswire
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial results and business highlights. To listen to the conference call by ph
ZacksAfter Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)
Evelo Biosciences, Inc. (EVLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- GlobeNewswire
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, today announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET. A live audio webcast of the panel will be available
- GlobeNewswire
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated – – EDP2939 Phase 2 data in psoriasis anticipated in 2H 2023 – CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intesti
ZacksDown -39.46% in 4 Weeks, Here's Why Evelo Biosciences, Inc. (EVLO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Evelo Biosciences, Inc. (EVLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- American City Business Journals
Flagship-backed biotech cuts nearly half its staff
A Flagship Pioneering spinout developing treatments for immune diseases is laying off 48 employees — about 45% of its staff.
BenzingaEvelo Biosciences' Atopic Dermatitis Study Fails, Observes Unusually High Placebo Response Rates
Evelo Biosciences Inc (NASDAQ: EVLO) said it observed an unusually high placebo response rate in the first three cohorts of the EDP1815 Phase 2 atopic dermatitis study, resulting in a missed primary endpoint. The company said it is working through the data to understand the very high placebo rates observed in the trial, which occurred with greater prevalence in certain geographic regions. The trial's fourth cohort, designed to test the faster release formulation, is fully recruited, and data fro
- Reuters
UPDATE 1-Evelo Biosciences to cut jobs, skin disease drug trial disappoints
Evelo Biosciences Inc said on Wednesday its skin disease treatment did not meet the main goal in a mid-stage trial, and added it would reduce its workforce to conserve cash amid macroeconomic concerns. Evelo did not disclose details on how many jobs it plans to cut. Evelo said the drug, EDP1815, had failed to reduce the size and severity of eczema in the first three patient groups of the mid-stage trial.
- GlobeNewswire
Evelo Biosciences Provides Clinical and Business Updates
– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed –– Clear path to registration trials for EDP1815 in psoriasis based on recently completed interactions with FDA, EMA and MHRA –– Dosing commenced in clinical study with first extracellular vesicle (EV) product candidate EDP2939 in January; Phase 2 data in psoriasis anticipated in 2H 2023 –– Optimizing operations and reducing workforce to focus
PR NewswireHorizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update
Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today provided its portfolio update for the fourth quarter ended December 31, 2022 and an update on the lending platform ("Horizon Platform") of Horizon Technology Finance Management LLC ("HTFM")
- GlobeNewswire
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced it has entered into a senior secured loan agreement with Horizon Technology Finance Corporation (Horizon) (Nasdaq: HRZN), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the
- Simply Wall St.
Evelo Biosciences, Inc. (NASDAQ:EVLO) insiders placed bullish bets worth US$575k in the last 12 months
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
- GlobeNewswire
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
Peer-reviewed article explains the immunology of the small intestinal axisCompany to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines, today announced the publication of a peer-reviewed article explaining the scientific basis of the Small Intestinal Axis1 and that it will hold a Science Symposium on Wednesday,
- GlobeNewswire
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first extracellular vesicle product candidate EDP2939 in psoriasis anticipated in 2H 2023 – - Continuing to advance regulatory discussions for registration trials for EDP1815 in psoriasis - CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology com
- GlobeNewswire
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 7:25 a.m. GMT. A live audio webcast of the presentation will be available he
- GlobeNewswire
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented biomarker data demonstrating the broad anti-inflammatory effects of EDP1815, the Company’s lead product candidate in inflammation, in a Phase 2 clinical trial in psoriasis. The data were presented in a poster at the 2022 EADV Congress in Milan, Ital